Sign in Subscribe

article

A collection of 642 issues

CRC Research Finding

Skip to content The CRC Digest ◆ Updated survival analysis for bevacizumab in metastatic CRC (Clinical Colorectal Cancer) This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026 The CRC Digest — crcdigest.com

KRAS-G12C and PIK3CA hotspot mutations help reclassify MUTYH variants

Skip to content The CRC Digest KRAS-G12C and PIK3CA hotspot mutations help reclassify MUTYH variants Researchers found that the somatic mutations KRAS-G12C and PIK3CA-Q546K are highly enriched in MUTYH-associated polyposis tumors and rarely seen in sporadic cases, making them useful for reclassifying uncertain MUTYH variants. (Human Mutation) This content is

MSI-H and dMMR prevalence characterized in Hispanic/Latino colorectal cancer populations

Skip to content The CRC Digest MSI-H and dMMR prevalence characterized in Hispanic/Latino colorectal cancer populations A systematic review and meta-analysis evaluated the prevalence of microsatellite instability-high and mismatch repair deficiency biomarkers across 1,195 colorectal cancer samples from Hispanic/Latino individuals in Latin America. (International Journal of Colorectal

Early-onset colorectal cancer shows distinct features in sporadic, proficient mismatch repair tumors

Skip to content The CRC Digest Early-onset colorectal cancer shows distinct features in sporadic, proficient mismatch repair tumors A study of 1,218 patients found that sporadic, proficient mismatch repair early-onset colorectal cancer (diagnosed under age 50) has unique clinicopathological characteristics and stage-adjusted outcomes compared to later-onset disease. (BMC Gastroenterology)

CRC Research Finding

Skip to content The CRC Digest ♥ Survivorship programs improve quality of life for colorectal cancer survivors A systematic review and meta-analysis of 22 randomized trials involving nearly 3,000 colorectal cancer survivors found that survivorship programs effectively enhance health-related quality of life. (Supportive Care in Cancer) This content is informational

CRC Research Finding

Skip to content The CRC Digest ◇ GDF15 Protein Linked to Chemotherapy Resistance in Colorectal Cancer Lab studies identified GDF15 as a key molecule driving resistance to 5-fluorouracil and oxaliplatin by promoting stem cell-like properties in colorectal cancer cells; high GDF15 expression in liver metastasis specimens was associated with early recurrence

Circulating Tumor DNA Shows Promise for Predicting Colorectal Cancer Recurrence

Skip to content The CRC Digest Circulating Tumor DNA Shows Promise for Predicting Colorectal Cancer Recurrence A review of current evidence suggests circulating tumor DNA has significant prognostic and predictive potential for detecting minimal residual disease and individualizing adjuvant therapy in colorectal cancer. (Klinická Onkologie) This content is informational only

Five Decades of Familial Adenomatous Polyposis Surveillance in Denmark

Skip to content The CRC Digest Five Decades of Familial Adenomatous Polyposis Surveillance in Denmark A study from the Danish Polyposis Register emphasizes the importance of lifelong endoscopic surveillance and tailored treatment strategies for FAP patients, who face elevated risks for duodenal and pancreatic cancers even after colectomy. (APMIS) This

Nous-209 Immunotherapy Targets Appear Early in Lynch Syndrome Precancers

Skip to content The CRC Digest Nous-209 Immunotherapy Targets Appear Early in Lynch Syndrome Precancers In a study of Lynch syndrome carriers, 83% of advanced adenomas and 58% of adenomas were mismatch repair-deficient, and the presence of Nous-209 mutations correlated strongly with microsatellite instability status, suggesting potential for preventive immunotherapy.

Prolonged Response to Pembrolizumab in BRAF V600E MSS Colorectal Cancer

Skip to content The CRC Digest Prolonged Response to Pembrolizumab in BRAF V600E MSS Colorectal Cancer A patient with BRAF V600E-mutant microsatellite-stable metastatic colorectal cancer achieved a prolonged response to pembrolizumab following a dynamic increase in tumor mutational burden. (The Oncologist) This content is informational only and does not constitute